Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 March 2018 Photo Leonie Bolleurs
Second triumph for young pollution and pharmaceutical researcher
Emmie Chiyindiko, winner of Famelab.

“I am grateful to be reaping the benefits of stepping out of my comfort zone. By facing the unfamiliar, that challenge will allow me to see what great things I am capable of,” said Emmie Chiyindiko, winner of Famelab 2018.

With FameLab, the world’s leading science communication competition, participants have just three minutes to win over the judges and crowd with a scientific talk that excels in content, clarity and charisma. Contestants from around the world participate, armed only with their wits and a few props.

Emmie won the Postgraduate School’s Three-Minute-Thesis competition for master’s level in 2017.

She said: “My research is based on the synthesis and characterisation of a series of unique metal complexes.” These complexes are used both as active pharmaceutical ingredients and cosmetic additives to reduce the detrimental effects of UV radiation on the skin. They are incorporated into anti-ulcer, gastro protective drugs, anti-asthmatic, lung disease drugs, with anti-cancer and anti-diabetic agents,” she said.

With her research she can also monitor air pollution. Formaldehyde is a known toxin to human health. “Using metal complexes, I am able to monitor the production of formaldehyde and consequently come up with exposure prevention methods,” said Emmie.

She believes that it is okay to not ”fit in“. “Mannerisms such as your quirks make you different and distinctive. Live your life intentionally, imprint your personal mark on this universe and always choose faith over fear.”

News Archive

Death may come in adorable little packages
2015-03-23

The main host of the Lassa virus is the Natal Mulimammate mouse.

Photo: Supplied

Postdoctoral researcher, Abdon Atangana, of the Institute for Groundwater Studies at the university recently published an article online about the Lassa Haemorrhagic fever in the Natural Computing Applications Forum. In addition to the terminal transmissible sickness recognised as Ebola haemorrhagic fever, there is another strain called Lassa haemorrhagic fever.

The disease is classified under the arenaviridae virus family. The first outbreaks of the disease were observed in Nigeria, Liberia, Sierra Leone, and the Central African Republic. However, it was first described in 1969 in the town of Lassa, in Borno State, Nigeria.

The main host of the Lassa virus is the Natal Mulimammate mouse, an animal indigenous to most of Sub-Saharan Africa. The contamination in humans characteristically takes place through exposure to animal excrement through the respiratory or gastrointestinal tracts.

Mouthfuls of air containing tiny particle of infective material are understood to be the most noteworthy way of exposure. It is also possible to acquire the infection through broken skin or mucous membranes that are directly exposed to the infective material.

“The aim of my research was to propose a novel mathematical equation used to describe the spread of the illness amongst pregnant women in West Africa. To achieve this, I used my newly-proposed derivative with fractional order called beta-derivative. Since none of the commonly used integral transform could be used to derive the solution of the proposed model, I proposed a new integral transform called Atangana-Transform, and used it, together with some iterative technique, to derive the solution of the model.

“My numerical simulations show that the disease is as deadly amongst pregnant women as Ebola,” Abdon said.

Abdon’s research was submitted to one of Springer’s top-tier journals with an impact factor 1.78. The paper was accepted and published February 2015.

Read more about Abdon’s research.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept